Greenwich LifeSciences initiated with an Outperform at Noble Capital

Noble Capital initiated coverage of Greenwich LifeSciences (GLSI) with an Outperform rating and $45 price target Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees “large market potential” for GLSI-100.